Purpose: There is uncertainty as to which anticoagulant should be used in non-valvular
atrial fibrillation (AF) with valvular heart disease. This systematic review and meta-analysis …

Background: Direct oral anticoagulants (DOACS) are approved for use in non-valvular atrial
fibrillation (AF). This systematic review and meta-analysis aimed to evaluate the efficacy and …

Abstract Introduction New oral anticoagulants (NOACs) are approved for use in nonvalvular
atrial fibrillation (AF). Objectives This study aimed to evaluate the efficacy and safety of …

Background Whether four direct oral anticoagulants (DOACs) are superior to warfarin
among Asians with non-valvular atrial fibrillation (NVAF) remains unclear in the real-world …

Anticoagulation therapy is an important method of preventing stroke in individuals with atrial
fibrillation (AF). Atrial fibrillation is a quivering or irregular heartbeat that can lead to blood …

Background The original non–vitamin K antagonist oral anticoagulant (NOAC) trials in
nonvalvular atrial fibrillation (AF) enrolled patients with native valve pathologies. The object …

Direct oral anticoagulants (DOACs) are indicated for stroke prevention in patients with
nonvalvular atrial fibrillation (NVAF), which, according to the American College of …

Background Current guidelines recommend direct-acting oral anticoagulants (DOACs) over
warfarin in patients with atrial fibrillation (AF) and valvular heart disease (VHD) without a …

Purpose: To systematically review available evidence of indirect comparisons from RCTs
and direct comparisons from observational studies regarding the comparative effectiveness …

Recent data suggest direct oral anticoagulants are as safe and efficacious as warfarin
among select patients with valvular heart disease and atrial fibrillation (AF). However, real …